Role of PD-L1 assessment in advanced NSCLC: does it still matter?

Anticancer Drugs. 2021 Nov 1;32(10):1084-1085. doi: 10.1097/CAD.0000000000001118.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / pathology*
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • B7-H1 Antigen / biosynthesis*
  • Biomarkers, Tumor
  • Brain Neoplasms / secondary
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology*
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors
  • pembrolizumab